Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
Fiche publication
Date publication
juin 2017
Journal
Clinical pharmacokinetics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DELMER Alain
Tous les auteurs :
Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D
Lien Pubmed
Résumé
Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Rituximab pharmacokinetics shows a time dependency possibly related to changes in the target antigen amount over time. The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on rituximab pharmacokinetics in CLL.
Mots clés
Antigens, CD20, metabolism, Antineoplastic Agents, blood, B-Lymphocytes, metabolism, Body Surface Area, Female, Genotype, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Lymphocyte Count, Male, Middle Aged, Models, Biological, Polymorphism, Genetic, Receptors, IgG, genetics, Rituximab, blood
Référence
Clin Pharmacokinet. 2017 06;56(6):635-647